Key facts
- Coding Bio’s last known valuation is $6.6M (Sep 2023).
- It has raised $3.6M across 1 recorded rounds; the latest was Seed Round ($3.6M) in Sep 2023.
- Notable investors include Metaplanet Holdings, Global Founders Capital, 2048 Ventures, BoxOne Ventures, The Venture Collective — 15 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Coding Bio
Funding rounds
1 roundsAbout Coding Bio
Developer of a cell discovery platform designed to accelerate the development of new targets for chimeric antigen receptors. The company's platform uses artificial intelligence to design cell therapies through automation and computation, enabling patients to recover from illness with the help of curative therapeutics.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2020
- Employees
- 19
- Website
- coding.bio/
- Ownership
- Privately Held (backing)
Coding Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Coding Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Coding Bio in its N-PORT filings yet. We sweep new filings monthly.